ACTIMMUNE
Drug
Horizon Pharma plc
Total Payments
$6.7M
Transactions
5,840
Doctors
2,159
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $270,280 | 675 | 384 |
| 2023 | $339,527 | 678 | 357 |
| 2022 | $324,103 | 807 | 428 |
| 2021 | $361,485 | 838 | 521 |
| 2020 | $334,536 | 551 | 345 |
| 2019 | $718,546 | 747 | 436 |
| 2018 | $1.8M | 735 | 472 |
| 2017 | $2.6M | 809 | 518 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.7M | 57 | 70.2% |
| Honoraria | $1.4M | 546 | 20.6% |
| Travel and Lodging | $209,253 | 584 | 3.1% |
| Food and Beverage | $179,675 | 4,438 | 2.7% |
| Consulting Fee | $135,570 | 31 | 2.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $89,000 | 33 | 1.3% |
| Charitable Contribution | $5,000 | 1 | 0.1% |
| Education | $2,058 | 145 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $1,700 | 5 | 0.0% |
Payments by Type
Research
$4.7M
57 transactions
General
$2.0M
5,783 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HER-2 POSITIVE BREAST | Horizon Pharma plc | $1.2M | 0 |
| MULTICENTER, SAFETY AND EFFICACY, OPEN-LABEL EXTENSION STUDY OF ACTIMMUNEINTERFERON -1B IN CHILDREN AND YOUNG ADULTS WITH FRIEDREICH'S ATAXIA | Horizon Pharma plc | $777,455 | 0 |
| EFFECT OF INF ON INNATE CELLS EFFECTS OF ACTIMMUNE ON IN VIVO GENE EXPRESSION BIOLOGICAL ACTIVITY MARKERS FUNCTIONAL ACTIVITY OF MYELOID CELL | Horizon Pharma plc | $300,000 | 0 |
| ECONS PHASE 2A STUDY OF INTERFERON GAMMA-1B FOR THE TREATMENT OF AUTOSOMAL DOMINANT TYPE 2 OSTEOPETROSIS | Horizon Pharma plc | $275,685 | 0 |
| HZNP-ACT-IIT-008 | Horizon Pharma plc | $250,000 | 0 |
| RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY, SAFETY | Horizon Pharma plc | $185,082 | 0 |
| HZNP-ACT-IIT-005 | Horizon Pharma plc | $152,143 | 0 |
| 2705 NCI2013-01779 | Horizon Pharma plc | $151,402 | 0 |
| LONG-TERM SAFETY EXTENSION STUDY OF ACTIMMUNE INTERFERON -1B IN CHILDREN AND YOUNG ADULTS WITH FRIEDREICHS ATAXIA | Horizon Pharma plc | $142,643 | 0 |
| POLGREEN OPEN-LABEL PHASE 12 STUDY WITH A SINGLE ARM OF INTERFERON GAMMA-1B TREATMENT OF OSTEOPETROSIS | Horizon Pharma plc | $141,896 | 0 |
| HZNP-ACT-IIT-009 | Horizon Pharma plc | $127,947 | 0 |
| A PHASE I-II STUDY OF INTERFERON-GAMMA PLUS WEEKLY PACLITAXEL | Horizon Pharma plc | $114,030 | 0 |
| Role of Interferon-gamma 1-b IFN- on Cells of the Innate Immune System Functional, Biochemical and Gene Expression Studies in Patients with Chronic Granulomatous Disease | Horizon Therapeutics plc | $102,943 | 0 |
| THE ROLE OF IFN SUPPLEMENTATION IN T CELL EFFECTOR FUNCTION IN PATIENTS WITH CHRONIC GRANULOMATOUS DISEASE | Horizon Therapeutics plc | $98,969 | 0 |
| THE ROLE OF IFN SUPPLEMENTATION IN T CELL EFFECTOR FUNCTION IN PATIENTS WITH CHRONIC GRANULOMATOUS DISEASE | Horizon Pharma plc | $95,009 | 0 |
| INVESTIGATOR-INITIATED RESEARCH | Horizon Therapeutics plc | $75,642 | 0 |
| ECONS PHASE 2A STUDY OF INTERFERON GAMMA-1B FOR THE TREATMENT OF AUTOSOMAL DOMINANT TYPE 2 OSTEOPETROSIS | Horizon Therapeutics plc | $73,872 | 0 |
| A PHASE II TRIAL OF PEMBROLIZUMAB AND INTERFERON GAMMA 1-B COMBINATION IMMUNOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED MYCOSIS FUNGOIDES AND SEZARY SYNDROME TREATMENT GROUP 1 AND IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA TREATMENT GROUP 2 | Horizon Therapeutics plc | $67,206 | 0 |
| ELUCIDATING THE TRANSCRIPTOME AND THE MECHANISTIC BASIS OF INTERFERON GAMMA ACTION IN X-CGD NEUTROPHILS | Horizon Therapeutics plc | $54,046 | 0 |
| POLGREEN OPEN-LABEL PHASE 12 STUDY WITH A SINGLE ARM OF INTERFERON GAMMA-1B TREATMENT OF OSTEOPETROSIS | Horizon Therapeutics plc | $52,313 | 0 |
Top Doctors Receiving Payments for ACTIMMUNE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Iowa City, IA | $4.7M | 64 |
| , MD | Pediatrics | Salt Lake City, UT | $230,720 | 154 |
| , M.D | Allergy & Immunology | Grand Rapids, MI | $199,427 | 188 |
| , MD, MS | Pediatric Allergy/Immunology | Charlotte, NC | $157,850 | 119 |
| , M.D | Internal Medicine | San Diego, CA | $151,277 | 156 |
| , MD | Pediatric Infectious Diseases | Chicago, IL | $147,507 | 152 |
| , M.D | Allergy & Immunology | Saint Petersburg, FL | $137,850 | 139 |
| , MBBS MD | Pediatrics | Minneapolis, MN | $66,138 | 63 |
| , M.D | Allergy & Immunology | Leominster, MA | $65,497 | 54 |
| , M.D., M.P.H | Pediatric Allergy/Immunology | Charleston, SC | $45,472 | 30 |
| , MB/BCHIR, PHD | Pediatric Infectious Diseases | Hartford, CT | $41,292 | 48 |
| , D.O | Allergy & Immunology | Carlisle, PA | $33,677 | 28 |
| , MD | Pediatrics | Philadelphia, PA | $32,841 | 24 |
| , MD | Pediatric Hematology-Oncology | Aurora, CO | $28,872 | 27 |
| , MD | Allergy & Immunology | Salt Lake City, UT | $28,751 | 29 |
| , M.D., PH.D | Allergy & Immunology | Los Angeles, CA | $27,098 | 32 |
| , M.D | Pediatrics | San Francisco, CA | $22,207 | 21 |
| , MD | Internal Medicine | Nashville, TN | $19,860 | 29 |
| , M.D. PH.D | Pediatrics | Philadelphia, PA | $19,568 | 19 |
| , CPNP | Pediatrics | Baltimore, MD | $19,026 | 33 |
| , MD | Pediatrics | Nashville, TN | $18,098 | 19 |
| , M.D | Allergy & Immunology | Baltimore, MD | $17,240 | 19 |
| , M.D | Internal Medicine | San Juan, PR | $16,185 | 27 |
| , MD | Allergy & Immunology | Phoenix, AZ | $13,003 | 22 |
| , M.D | Pediatric Allergy/Immunology | Aurora, CO | $12,241 | 14 |
Ad
Manufacturing Companies
- Horizon Pharma plc $4.4M
- Horizon Therapeutics plc $2.1M
- Amgen Inc. $270,280
Product Information
- Type Drug
- Total Payments $6.7M
- Total Doctors 2,159
- Transactions 5,840
About ACTIMMUNE
ACTIMMUNE is a drug associated with $6.7M in payments to 2,159 healthcare providers, recorded across 5,840 transactions in the CMS Open Payments database. The primary manufacturer is Horizon Pharma plc.
Payment data is available from 2017 to 2024. In 2024, $270,280 was paid across 675 transactions to 384 doctors.
The most common payment nature for ACTIMMUNE is "Unspecified" ($4.7M, 70.2% of total).
ACTIMMUNE is associated with 20 research studies, including "TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HER-2 POSITIVE BREAST" ($1.2M).